文献速递免疫规划传染病防控与疫情报告

加纳COVID-19疫苗对SARS-CoV-2相关SARI住院的保护效果

COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
PubMed 文献 · Vaccine · 2026-02-17

在加纳32家流感监测医院中,对2022年6月至2024年3月≥15岁SARI住院患者开展检测阴性病例对照研究,1796例中118例SARS-CoV-2阳性。末剂疫苗接种至发病≤179天时,绝对VE为22%(95%CI -107-70),年VE为19%(95%CI -113%-50%),6个月后减弱,估计不精确。

要点

  • 加纳SARI住院患者中,接种COVID-19疫苗后6个月内对SARS-CoV-2住院有保护趋势。
  • 末剂接种≤179天的绝对VE为22%(95%CI -107-70),年VE为19%(95%CI -113%-50%)。
  • 疫苗保护效果在接种6个月后减弱,且估计值不精确。

核心结论

  • 研究期间加纳COVID-19疫苗可能预防了接种后6个月内的COVID-19相关SARI住院,但效果估计不精确。
  • 观察到的保护模式与其他地区报告一致。

研究设计与样本

  • 检测阴性病例对照研究,纳入2022年6月至2024年3月加纳32家流感监测医院≥15岁SARI住院患者。
  • 共1796例纳入分析,其中SARS-CoV-2阳性118例(7%),阴性1678例(93%)。

主要发现

  • 1796例中男性929例(52%),女性867例(48%),41%年龄超过60岁,167例(9%)报告至少一种慢性病。
  • SARS-CoV-2阳性者中29例(25%)至少接种一剂疫苗,阴性者中412例(25%)至少接种一剂疫苗。
  • 50例孕妇中5例(10%)SARS-CoV-2检测阳性。
  • 末剂疫苗接种至发病≤179天的绝对VE为22%(95%CI -107-70),年VE为19%(95%CI -113%-50%),6个月后减弱。

临床怎么用

  • 在SARI监测中可继续评估COVID-19疫苗对住院的保护效果,关注接种后6个月内的保护趋势。
  • 解读VE估计时需注意置信区间宽泛和不精确性。

局限性

  • 效果估计不精确,置信区间宽且包含无效值。
  • 研究仅纳入参与流感监测的32家医院,可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of vaccines to urgently respond to the COVID-19 pandemic generated the need for monitoring vaccine effectiveness in the context of new viral variants and changing epidemiology. This study measured the COVID-19 vaccine effectiveness (VE) against laboratory-confirmed SARS-CoV-2 in hospitalised patients diagnosed with severe acute respiratory infections (SARI) in Ghana. METHODS: This was a test-negative, case-control study, among patients aged ≥15 years, attending 32 hospitals that participate in influenza surveillance system between June 2022 and March 2024. Naso-and oropharyngeal swabs were tested for SARS-CoV-2 by PCR. Medical and vaccination data were obtained. VE was estimated as one minus adjusted odds of vaccination among participants, expressed as a percentage, and the reference was either unvaccinated cases (absolute VE) or unvaccinated plus those vaccinated >12 months prior to symptom onset (annual VE). RESULTS: Of 1974 SARI patients, 1796 (91%) were enrolled, including 929/1796 males (52%) and 867/1796 females (48%); 41% were above 60 years old. At least one chronic medical condition was reported in 167/1796 (9%) participants. A total of 118/1796 (7%) tested positive for SARS-CoV-2, of whom 29 (25%) have received at least one dose of vaccine (Sputnik V, Vaxzevria, JCovden, or Comirnaty). Of the 1678 (93%) who tested negative for SARS-CoV-2, 412 (25%) received at least one dose of vaccine. Among pregnant women (n = 50), 5 (10%) tested positive for SARS-CoV-2 Absolute and annual VE against COVID-19 SARI hospitalization were respectively 22% (95% CI, -107-70) and 19% (95% CI, -113%-50%) for last dose of vaccine received up to 179 days prior but waned after 6 months. CONCLUSION: COVID-19 vaccines may have prevented COVID-19-associated SARI hospitalizations in the first 6 months over the study period in Ghana, and a pattern of protective effective was observed, consistent with report from other settings, although effect estimates were imprecise.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Amoako N, Cohuet S, Adjei MR, et al. COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024. Vaccine. 2026. PMID: 41708421. doi:10.1016/j.vaccine.2026.128310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。